“Treatment outcome in patients with HCV Genotype-3a Infection, Treated with 24-Weeks Dual Therapy (Sofosbuvir and Ribavirin)”, mfm, vol. 28, no. 11, May 2024, Accessed: Feb. 01, 2026. [Online]. Available: https://medicalforummonthly.com/index.php/mfm/article/view/4275